Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).-Reference-Cited by-同舟云学术

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

Published:2015-05-20 Issue:15_suppl Volume:33 Page:8010-8010
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Spira Alexander I.¹,Park Keunchil²,Mazières Julien³,Vansteenkiste Johan F.⁴,Rittmeyer Achim⁵,Ballinger Marcus⁶,Waterkamp Daniel⁷,Kowanetz Marcin⁶,Mokatrin Ahmad⁶,Fehrenbacher Louis⁸

Affiliation:

1. Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, VA

2. Division of Hematology & Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

3. Hôpital Larrey CHU Toulouse, Toulouse, France

4. University Hospital KU Leuven, Leuven, Belgium

5. Lungenfachklinik Immenhausen, Kassal, Germany

6. Genentech, Inc., South San Francisco, CA

7. F. Hoffmann-La Roche Ltd., Basel, Switzerland

8. NRG Oncology/NSABP, and Kaiser Permanente Northern California, Novato, CA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.8010

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status;Healthcare;2023-04-09

2. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors;Cancers;2022-12-13

3. PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?;Clinics and Practice;2022-08-24

4. Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents;Healthcare;2022-04-07

5. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?;International Immunopharmacology;2022-02